Entering text into the input field will update the search result below

AbbVie’s guidance for Skyrizi and Rinvoq lifts remaining overhang - Morgan Stanley

Jan. 12, 2022 10:52 AM ETAbbVie Inc. (ABBV) StockBy: Dulan Lokuwithana, SA News Editor21 Comments

Abbvie

vzphotos/iStock Editorial via Getty Images

  • Morgan Stanley has welcomed the recent sales guidance issued by AbbVie (ABBV -0.4%) for Rinvoq (upadacitinib) and Skyrizi (risankizumab).
  • In a press release on Tuesday ahead of its presentation at the ongoing J.P. Morgan Healthcare

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABBV--
AbbVie Inc.